KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Non-cash Items: 2014-2018

Historic Non-cash Items for Neogenomics (NEO) over the last 1 years, with Dec 2018 value amounting to $2.5 million.

  • Neogenomics' Non-cash Items rose 19.28% to $2.5 million in Q4 2018 from the same period last year, while for Dec 2018 it was $2.5 million, marking a year-over-year increase of 19.28%. This contributed to the annual value of $2.5 million for FY2018, which is 50.38% down from last year.
  • Per Neogenomics' latest filing, its Non-cash Items stood at $2.5 million for Q4 2018, which was up 19.28% from $2.1 million recorded in Q4 2017.
  • In the past 5 years, Neogenomics' Non-cash Items ranged from a high of $5.1 million in Q4 2016 and a low of $900,000 during Q1 2015.
  • Moreover, its 3-year median value for Non-cash Items was $2.3 million (2017), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Neogenomics' Non-cash Items skyrocketed by 104.30% in 2015, and later slumped by 58.76% in 2017.
  • Quarterly analysis of 5 years shows Neogenomics' Non-cash Items stood at $2.4 million in 2014, then spiked by 104.30% to $4.9 million in 2015, then climbed by 4.92% to $5.1 million in 2016, then slumped by 58.76% to $2.1 million in 2017, then increased by 19.28% to $2.5 million in 2018.
  • Its Non-cash Items stands at $2.5 million for Q4 2018, versus $2.1 million for Q4 2017 and $2.1 million for Q3 2017.